<?xml version="1.0" encoding="UTF-8"?>
<p id="para0008">Continuing availability of blood products is a prerequisite for planning HCT, given that blood supply has been a major issue during the pandemic. The possibility of reducing the threshold for blood product transfusion should be discussed at the beginning of HCT. In addition, blood loss prevention strategies (eg, minimizing blood draws or treatment with tranexamic acid if clinically permissible) should be maximized 
 <xref rid="bib0010" ref-type="bibr">[10]</xref>. The use of pediatric tubes and reassessment of scheduled laboratory work may be useful as well.
</p>
